Form 4 for AGEN AGENUS INC
Accepted 2023-01-09 00:00:00 ET · period of report 2023-01-05 · accession 0000899243-23-001320 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-09 | 2023-01-05 | AGEN | O'Day Steven J | Chief Medical Off | A - Grant | $2.45 | +109.4K | 272.4K | +67% | +$268.0K |
| D | 2023-01-09 | 2023-01-05 | AGEN | O'Day Steven J | Chief Medical Off | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-05 | A | A | 109,381 | $2.45 | 272,384 | D | — | — | (F1) Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023. (F2) $2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date. |
| 2 | Derivative | Stock Option | 2023-01-05 | A | A | 200,000 | $0.00 | 200,000 | D | $2.45 · — to 2033-01-05 | 200,000 Common Stock | (F3) Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter. |